Intranasal Wharton's Jelly-Derived Mesenchymal Stem Cell Therapy, Alone or in Conjunction With Therapeutic Hypothermia, Alleviates Neonatal Hypoxic-Ischemic Brain Injury in Mice.

ABSTRACT:

Objective

Neonatal hypoxic-ischemic brain injury (HIBI) caused by perinatal asphyxia is a primary cause of long-term neurological morbidity. Hypothermia is the sole available clinical intervention despite its limited efficacy. Intranasal mesenchymal stem cells (MSCs) show promise for the treatment of HIBI. This study explores the efficacy, migration, treatment window, and therapeutic mechanisms of intranasally applied Wharton's jelly-derived MSCs (WJ-MSCs) in a neonatal HIBI mouse model, and assesses its therapeutic benefit in conjunction with hypothermia.

Methods

Nine-day-old C57BL/6 mice underwent hypoxia-ischemia (HI), with or without hypothermia, and were intranasally dosed with 0.1 to 2.0 × 10⁶ WJ-MSCs, at 3 or 10 days post-HI. WJ-MSCs were traced using diffe

SUBMITTER: de Theije CGM 

PROVIDER: S-EPMC12682942 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature